- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02334280
Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI
The goal of this project, which has not changed, is to evaluate the statewide implementation of a two-component intervention (health promotion plus academic detailing) with respect to consumer outcomes and changes in provider prescribing. The intervention, called In SHAPE, is delivered to people with serious mental illness (SMI) by two community mental health clinics (CMHCs). These CMHCs are compared to two CMHCs delivering usual-care to individuals with SMI. The specific aims of this study are:
- Evaluate person-level and provider-level outcomes including: (a) consumer health behaviors, health indicators, mental health indicators, and acute health service utilization, (b) provider prescribing practices and program fidelity, and (c) program costs.
- Evaluate system-level outcomes including: (a) consumer health behaviors and health indicators, (b) provider prescribing and program fidelity, and (c) acute services use.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03766
- West Central Behavioral Health
-
Manchester, New Hampshire, United States, 03103
- Mental Health Center of Greater Manchester
-
Nashua, New Hampshire, United States, 03060
- Greater Nashua Mental Health Center at Community Council
-
Salem, New Hampshire, United States, 03079
- Center for Life Management
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 21 or older
- Serious mental illness defined by (a) an axis I diagnosis of major depression, bipolar disorder, schizoaffective disorder, or schizophrenia, (b) moderate impairment across multiple areas of psychological functioning, or (c) Global Assessment of Functioning (GAF) score less than 61
- Able to provide voluntary informed consent for participation in the study by the participant or by the participant's legally designated guardian or conservator
- Poor fitness as indicated by BMI > 25 or failure to adhere to the US Department of Health and Human Services Physical Activity Guidelines for Americans, i.e., at least 2.5 hr/week of moderate or 75 min/week of vigorous activity in more than one session
- Medical clearance for participation in an exercise and dietary modification program by a physician, physician assistant, or nurse practitioner
- An expressed willingness to participate in a diet and exercise program
- Currently taking an atypical antipsychotic medication
- Able to walk a city block
- Responsible for choice of foods and how they are prepared
Exclusion Criteria:
- Currently residing in a nursing home or group home
- Terminal physical illness expected to result in the death of the study subject within one year
- Primary diagnosis of dementia, co-morbid diagnosis of dementia, or significant cognitive impairment as indicated by a Mini-Mental State Examination (MMSE) score < 24
- Inability to speak and understand English
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: In SHAPE
In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
|
In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
|
No Intervention: Usual-Care Control
Usual-care consumers agreed to delay participation in In SHAPE for 12 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in exercise capacity
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in exercise capacity measured by the 6-minute walk test.
|
baseline, 6-, 12-, and 24-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-reported physical activity
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in self-reported physical activity measured with International Physical Activity Questionnaire (IPAQ)
|
baseline, 6-, 12-, and 24-months
|
Change in dietary behaviors
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in dietary behaviors measured with the Block Food Frequency Questionnaire (FFQ)21 and the Questionnaire on Eating and Weight Patterns (QEWP).
|
baseline, 6-, 12-, and 24-months
|
Change in stage of change
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in stage of change measured with the Weight Loss Behavior-Stage of Change Scale (WLB-SOC) 23 to assess stage of change for engaging in healthy eating and exercise behaviors.
|
baseline, 6-, 12-, and 24-months
|
Change in eating behavior
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in eating behavior measured with the Dutch Eating Behavior Questionnaire which includes 13 questions assessing emotional eating and 10 questions related to external eating behaviors
|
baseline, 6-, 12-, and 24-months
|
Change in physical measurement
Time Frame: baseline, 6-, 12-, and 24-months
|
Including height, weight, pulse, CO2 level, lung capacity from spirometer, variables from impedance measure such as percentage of body fat and percentage of lean muscle mass, cholesterol and triglyceride levels from finger stick (cholesterol data for data points that have already passed will be collected from participants' clinic and hospital records), waist circumference: BMI derived from height and weight.
|
baseline, 6-, 12-, and 24-months
|
Change in smoking and substance use
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in smoking and substance use measured by questions developed for R01DA021245, "Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia," and questions from the "Quit Smoking Decision Aid"( developed by Ferron and Brunette, CPHS # 180) to ascertain smoking frequency, quantity, and cessation attempts
|
baseline, 6-, 12-, and 24-months
|
Change in psychological functioning (depression, negative symptoms, and self-efficacy).
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in psychological functioning measured by the Center for Epidemiologic Studies Depression Scale,Scale to Assess Negative Symptoms,16 and the Self-Rated Abilities for Health Practices Scale will be used to assess these constructs.
|
baseline, 6-, 12-, and 24-months
|
Change in social functioning
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in social functioning measured by the Social Network Questionnaire and Lehman Social Contact Scale.
|
baseline, 6-, 12-, and 24-months
|
Change in family contact
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in family contact measured by the Revised Family Contact Questionnaire.
|
baseline, 6-, 12-, and 24-months
|
Change in social support and eating habits
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in the impact of social support on eating habits measured by the Social Support and Eating Habits Survey
|
baseline, 6-, 12-, and 24-months
|
Change in social support and exercise
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in the impact of social support on exercise behaviors measured by the Social Support and Exercise Survey
|
baseline, 6-, 12-, and 24-months
|
Change in comorbid medical illness
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in comorbid medical illness measured using a medical problems list.
|
baseline, 6-, 12-, and 24-months
|
Change in medications
Time Frame: baseline, 6-, 12-, and 24-months
|
Change in medications measured by gathering information from participants about type, dose, and frequency of all prescribed medications.
|
baseline, 6-, 12-, and 24-months
|
Change in service use
Time Frame: baseline, 6-, 12-, and 24-months
|
Measured change in service use based on a measured designed for the In SHAPE studies to collect self-reported use of emergency services and hospitalizations.
|
baseline, 6-, 12-, and 24-months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stephen J Bartels, MD, MS, Dartmouth-Hitchcock Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- InSHAPE Implementation Study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
Central Institute of Mental Health, MannheimNot yet recruitingSchizophrenia | Treatment Resistant SchizophreniaGermany
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Rakitzi, StavroulaActive, not recruiting
Clinical Trials on In SHAPE
-
Dartmouth-Hitchcock Medical CenterRobert Wood Johnson Foundation; Endowment for HealthCompletedMental IllnessUnited States
-
Dartmouth-Hitchcock Medical CenterNational Institute of Mental Health (NIMH)CompletedSchizophrenia | Schizoaffective Disorder | Bipolar DisorderUnited States
-
Dartmouth-Hitchcock Medical CenterCompletedSchizophrenia | Schizoaffective Disorder | Bipolar Disorder | Major Depressive DisorderUnited States
-
Fonterra Research CentreSprim Advanced Life SciencesCompleted
-
Universidad Autonoma de Baja CaliforniaUnknown
-
TetraLogic PharmaceuticalsPPD; The Leukemia and Lymphoma Society; Veristat, Inc.; Therapeutics, Inc.CompletedLymphoma, T-Cell, CutaneousUnited States
-
Shape Medical Systems, Inc.National Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingPulmonary Arterial HypertensionUnited States
-
The Miriam HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedObesityUnited States
-
Seoul National University HospitalCompletedDouble Lumen Tube IntubationKorea, Republic of
-
Yale UniversityRecruitingPerioperative/Postoperative Complications | Aerobic CapacityUnited States